Archive

Select one or more of the webinars you wish to view and click the "Download" button. You will be asked to fill out a brief form in order to receive the webex links.

Download

JUL 2014 23
Discover a new streamlined workflow for HIV variant calling
More Info +

 

In this webinar recording, we’ll explore an end-to-end solution for identifying mutation and predicting HIV resistance.


● Discover how ultra-deep sequencing on the MiSeq Instrument enables the identification of HIV

● Learn about the newly published HIV bioinformatics pipeline and how easy it is to use

● Optimize your HIV Variant workflow from sample preparation to discovery

Microbiology & infectious disease
JUN 2014 25
Counting on Illumina – Application Focus: RNA-Seq
More Info +

Listen to our “Counting on Illumina" webinar where the application focus is RNA-Seq.   In this session, we provide an overview of this powerful technique, including library preparation options and issues when transitioning from microarrays.

Human Genetics & Genetic Disease
JUN 2014 17
Advancing technologies to improve IVF outcomes
More Info +

Chromosome aneuploidy (abnormal chromosome number) is a major cause of IVF failure, pregnancy loss, and in rare cases abnormal pregnancy and live birth. Most aneuploidies arise during the final stages of egg development as well as the first few divisions after fertilization. These aneuploidies increase exponentially with maternal age in the decade preceding menopause. Recent evidence suggests that the eggs and embryos of younger patients also have a relatively high incidence of aneuploidy. Existing 24sure technology from Illumina now allows chromosome screening of all 24 chromosomes from a single cell enabling selection of embryos with normal number of chromosomes for embryo transfer. 24sure is offered by many of the leading IVF centers worldwide either in-house or via a service laboratory. To date over 350,000 clinical biopsies have been processed using 24sure. In addition to existing technology, new solutions from Illumina based on Next Generation Sequencing (NGS) will be discussed.

Reproductive & Genetic Health
JUN 2014 10
Enable gene expression profiling and fusion detection in FFPE samples
More Info +

Millions of archival tissue samples, particularly formalin-fixed paraffin-embedded (FFPE) derived samples, provide a large vault of information for disease research. Typically, these samples are associated with long-term phenotypic data that may yield insight in gene expression changes that occur during various disease states. Unfortunately, the fixation process and storage of FFPE samples frequently leads to high RNA degradation and generally offers limited sample material, making it difficult to perform reliable, reproducible transcriptome analysis. While it is possible to derive usable RNA from FFPE samples, the current analysis methods produce highly variable results or often require expensive deep sequencing.

Next generation RNA sequencing is an ideal platform to access FFPE tissue samples for research, as it offers extensive functional genomic information. In this webinar, learn how researchers can leverage new technology to conduct cost-effective gene expression, profiling transcriptome analysis and fusion detection studies using RNA-sequencing to analyze difficult samples.

Sequencing
MAY 2014 28
On the forefront of transformation: Genomic applications in oncology
More Info +

The emergence of next-generation sequencing (NGS) and extensive collaboration with the cancer community have made possible a new understanding of the genes and pathways that drive tumor growth. These advances help propel targeted pharmaceutical development and bring us closer to the realization of precision medicine. As a leader in NGS technology, Illumina is investing in the development of novel clinical oncology solutions. Join our Medical Affairs leadership team to learn about the basic principles of next-generation sequencing. Explore the applications of genomics in oncology for germline risk prediction and precision medicine, including how NGS demonstrates the importance of circulating nucleic acids for molecular monitoring.

Cancer Genomics
APR 2014 29
Lungs, Germs, and Metabolites: A Cystic Fibrosis Story
More Info +

Dynamic microbial and viral communities constantly inhabit our bodies, encoding the majority of the unique genes that alter processes throughout our bodies and our lives. Persistent and unique viral and microbial communities are associated with every human, and they are powerful indicators of health and disease. Metagenomics, metabolomics, microbiology and ecological statistics can be used to answer questions about how microbes and viruses affect human health.

Next-Generation sequencing has enabled a torrent of recent discoveries about the composition and activity of human-associated microbial communities. In this webinar, we present recent work enabled by microbial DNA sequencing of human samples from healthy people and cystic fibrosis (CF) patients. Earlier and more specific diagnosis and treatment of periods of worsened symptoms known as pulmonary exacerbations in CF may be possible using paired metabolomic and metagenomic approaches to uncover biomarkers of disease state.

 
Microbiology & infectious disease
APR 2014 25
Best Practices for Obtaining RNA Sequencing Data from Formalin-fixed Paraffin-embedded (FFPE) Samples
More Info +

Webinar hosted by Expression Analysis

Formalin-fixed Paraffin embedded (FFPE) tissues present many sample preparation, extraction and method development challenges. Despite these difficulties, interest in genomic analysis of FFPE samples remains high, and large collections of clinically-annotated FFPE material await analysis. The presenter will describe the methods and best practices based on the extensive work Quintiles has performed analyzing both RNA and DNA from FFPE samples.

This webinar is intended to help genomic researchers better understand technical hurdles in the analysis of FFPE-derived RNA to:

  • Learn how EA has overcome challenges inherent in FFPE samples
  • Gain insight into experimental design considerations
  • Learn how to exploit your collection of FFPE material

 By attending the webinar you will learn:

  • How RNA sequencing data derived from fresh frozen and FFPE material can be compared
  • How to design experiments that obtain meaningful data from your FFPE samples

 

Sequencing
APR 2014 03
Transform the future of oncology with genomics
More Info +

Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection, tumor profiling, and gene expression studies. Our expanding oncology portfolio includes new tools that aid the discovery, identification, and analysis of cancer variants.

Join us for a review of recent advances in Illumina sample-to-data solutions, from whole-genome, RNA, and targeted sequencing, to epigenetic analysis, germ line risk assessment, and cytogenetics. Learn how these transformative solutions are now delivering relevant oncological information into the hands of translational and clinical researchers. Hear about groundbreaking developments in cancer genomics from around the world, including:

  • Whole-genome and targeted sequencing of DNA and RNA
  • Epigenetic analysis, germ line risk investigations and cytogenetics
  • Single cell sequencing to understand tumor heterogeneity
  • Deep sequencing of circulating nucleic acids as non-invasive bio markers

 

Cancer Genomics
MAR 2014 26
The Human Virome in Health and Disease
More Info +

The human virome—the collection of all the viruses within the human body—includes chronic and transient infections, endogenous retroviruses, and large bacteriophage populations that prey on human-associated bacteria. Recent studies have revealed that the human virome contains a high degree of variation. After sequencing and analyzing virome samples from healthy and diseased individuals on an Illumina HiSeq® System, researchers found that most viral contigs are novel sequences and viral communities vary greatly between individuals.

These findings provide insight into the variation between viromes, indicating that factors such as diverse viral predators, rapid viral evolution within the human body, and disease can affect the virome community. This webinar discusses the viral communities inhabiting the human body and how the virome affects human health.

Microbiology & infectious disease
MAR 2014 11
Karyomapping—A Rapid PGD Solution for Single-Gene Disorders
More Info +

Preimplantation Genetic Diagnosis (PGD) can be used where there is a risk of severe genetic disorders being inherited from parents, whether the couple has a family history of a genetic disorder or has a child affected by a genetic disease. Currently, PGD is often performed by examining the inheritance of short tandem repeats (STRs) adjacent to specific disease loci. Unfortunately, this method is complex and must be developed individually for each genetic disorder and each couple, making it time-consuming and limiting availability.

Karyomapping offers a faster, more accurate, and robust alternative to STR analysis for PGD. Using genome-wide linkage-based analysis, karyomapping detects single-gene disorders from as little as a single embryonic cell. Embryos that do not carry the defective gene can be identified and selected for transfer and subsequent implantation.

Join Professor Alan Handyside, one of the pioneers of karyomapping, and Dr. Alan Thornhill as they introduce the Illumina karyomapping solution, including the Infinium HumanKaryomap-12 BeadChip. This karyomapping assay targets ~300,000 of the most informative genomic markers resulting in comprehensive genome-wide analysis at the single-cell level.

Reproductive & Genetic Health
MAR 2014 03
16S rRNA sequencing: From DNA extraction to entire microbial community analysis
More Info +

Working closely with the microbial community, we’ve developed a powerful next generation sequencing solution that enables researchers to analyze an entire microbial community within a sample, including species that may not be identified otherwise. This culture-free method eliminates the time and expense involved in growing pure cultures and individually sequencing each type of bacteria.

Discover how you can leverage these next generation sequencing solutions to initiate and accelerate your own 16S rRNA studies.

Topics include:

  • An overview of the streamlined 16S rRNA metagenomics sequencing protocol
  • Discussion of analysis options with MSR and BaseSpace
  • Live demonstration of the BaseSpace 16S app
  • Case study conversation
    • A comparison of 16s metagenomic sequencing on MiSeq and 454
    • Desert tortoise conservation – disease surveillance and diagnosis
Microbiology & infectious disease
FEB 2014 18
NextSeq 500 Delivers Power and Flexibility for Cancer and Genetic Disease Studies
More Info +

GS-based variant detection is central to cancer and genetic disease studies, with the promise of enabling more accurate prognoses and more effective therapeutics. Using whole-genome, whole-exome, and RNA sequencing, large international projects such as The Cancer Genome Atlas (TCGA) and others have contributed greatly to the catalog of somatic driver mutations that underlie tumorigenesis and progression. The methods that powered these research strategies are now accessible to every lab with the NextSeq 500 system. Combining the power and accuracy of Illumina high-throughput sequencing with the speed, simplicity, and affordability of a desktop system, NextSeq 500 delivers multiple sequencing applications on one platform. The NextSeq 500 System is capable of sequencing a whole human genome at 30× in one run, and delivers exceptional workflow flexibility for other sequencing applications, including exome and RNA sequencing. Simple, cartridge-based reagents and configurable run modes allow researchers to quickly tailor experiments ranging from gene expression to complex whole-transcriptome profiling, on a single NGS system. Workflow improvements and expansions, including sample prep automation, run monitoring, data analysis, and storage using cloud or onsite options, will continue to improve the utility of NGS for the research needs of today and tomorrow.

Human Genetics & Genetic Disease
FEB 2014 04
Somatic Variant Discovery and Translation in Cancer Genomics – Next Generation Sequencing Solutions
More Info +

Next-generation sequencing (NGS)-based detection of somatic variants in tumor samples is a powerful tool to uncover the molecular drivers associated with different cancer types. This technology holds promise to enable more accurate prognoses and more effective therapy decisions – the foundation necessary to achieving precision medicine. Using whole-genome, whole-exome, and RNA-Seq, large international projects, such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), have contributed greatly to the catalog of somatic driver mutations that underlie tumorigenesis and progression in many common and rare cancers. These discoveries provide basic research and drug development communities direction to focus on the targets of greatest impact in the war on cancer. In the clinical research and oncology communities, similar sequencing strategies have emerged as a powerful weapon to further understand variation in the clinical course of various cancer types. 

These strategies are now accessible to every lab with Illumina’s new NextSeq 500 system. Using a powerful combination of sample preparation, sequencing, and informatics methods, Illumina now enables researchers to perform the same groundbreaking cancer analysis pioneered by groups such as TCGA and ICGC in their labs. This experimental design is more accessible than ever before. Join us to learn how researchers are using this comprehensive approach to continue to discover the biology of cancer and translate discoveries faster than ever before.

Cancer Genomics
NOV 2013 26
Creating, Expanding, and Streamlining Your Next-Generation Sequencing Portfolio using the TruSight™ One Sequencing Panel and VariantStudio
More Info +

 

Building a comprehensive sequencing portfolio with individual panels for each condition of interest presents numerous developmental and managerial complications. To help you overcome this challenge and streamline your sequencing portfolio while maximizing assay offerings, Illumina offers the TruSight One Sequencing Panel. TruSight One is a single, large sequencing panel targeting more than 4,800 genes and covering 12 Mb of genomic content. Combining TruSight One with the VariantStudio data analysis tool creates the simplest sample-to-report workflow that can replace dozens, if not hundreds, of small, individual sequencing panels and assays. The unmatched coverage uniformity of TruSight One facilitates high levels of multiplexing, enabling sequencing of trios on a single MiSeq flow cell and 36 samples on a single HiSeq flow cell.

Human Genetics & Genetic Disease:Sequencing:Software
OCT 2013 29
GenomeStudio Software for Automated Polyploid Clustering
More Info +

Many plant species are polyploid organisms with multiple homologous chromosomes, which often complicates genetic analysis. Illumina has developed the GenomeStudio Polyploid Clustering Module, which features powerful DBSCAN and OPTICS algorithms, to help researchers analyze genotyping data from polyploid genomes.

This webinar, presented by Cindy Lawley, Ph.D., Global Agriculture Consortia Program Manager at Illumina, demonstrates how to use the Polyploid Clustering Module. Topics include: starting a project, optimizing cluster detection sensitivity, manually adjusting clusters, importing cluster positions, and exporting cluster data. The webinar also covers analysis of the wheat genome to demonstrate how to use the Polyploid Clustering Module to study a complex genome.

Agriculture Genomics
OCT 2013 24
Molecular Pathology Reimbursement: Outcome of the 2013 Medicare Gapfilling Process
More Info +

This webinar summarizes the outcome of the recently concluded Medicare gapfilling process for 114 new molecular pathology (MoPath) codes that were implemented in 2013. The presentation will address the final 2013 regional rates for these codes, as well as the implications for national payment rates in 2014. We will then look ahead to additional upcoming changes in the molecular diagnostic reimbursement landscape and the potential impact on clinical laboratories.

Diagnostics
OCT 2013 11
Personal genome sequencing and the future of healthcare, My experience at Understand Your Genome
More Info +

Illumina coined a new verb – “get genomed” – in support of Understand Your Genome, an event where participants get “genome-sequenced” and “genome-educated.” During this webinar, I will discuss my personal experience at Understand Your Genome, where I had my genome sequenced, received the raw data on an iPad, and viewed reports in the MyGenome App. Join me in a discussion of the role of whole genome sequencing in modern medicine and its impact on the future of health care.

Human Genetics & Genetic Disease
SEP 2013 10
Deep sequencing of HIV: Detection of Drug Resistance Variants and Tracking of Viral Haplotypes
More Info +

HIV drug resistance testing has become an integral part of HIV clinical care. Commercially available genotypic assays identify drug resistance mutations through population sequencing of regions of the HIV protease and reverse transcriptase genes. However, these assays are insensitive to drug resistance variants when present at levels comprising less than 10 to 20 percent of the virus population.

By contrast, ultradeep sequencing allows the identification of HIV nucleotide variants and variant haplotype signatures present at <1% in patient samples. Tracking of viral haplotypes, which requires long-sequence read lengths, is particularly useful in determining whether sequentially expressed dual infections are the consequence of viral evolution, co-infection, or superinfection.

This webinar presents insight into the characterization of HIV by next-generation sequencing, including data obtained from a comparison of HIV drug-resistance variant detection in a 465-base region of HIV reverse transcriptase by the Illumina MiSeq and Roche 454 GS FLX+ platforms.

Microbiology & infectious disease
AUG 2013 15
Implementing Informatics Solutions to Support Genomics
More Info +

The Human Molecular Genetics Center at the Medical College of Wisconsin has implemented an efficient informatics solution to support genomics sequencing runs using Illumina systems. Jaime Wendt Andrae will discuss how they implemented the beta-version of Clarity Run Manager to enable sample tracking and automation of Illumina sequencing runs. Aubree Hoover will briefly introduce this new version of Clarity Run Manager, a free solution for managing projects and samples, and easily creating sample sheets for Illumina instruments.

Informatics
AUG 2013 07
Ground-breaking study, identifying a causal gene mutation for two dissimilar neurological diseases
More Info +

Dr. Bryan Traynor and his team participated in a ground-breaking international study, identifying a causal gene mutation responsible for two dissimilar neurological diseases, ALS and FTD. As members of a worldwide consortium, his research team used next-generation sequencing to identify a large hexanucleotide repeat that disrupts the C9ORF72 gene located on chromosome 9. The mutation accounts for approximately 40% of all familial cases of ALS and FTD in European and North American populations, and also ~1% of Alzheimer&rsquo;s disease cases. ALS, also known as Lou Gehrig&rsquo;s disease, is a fatal neurodegenerative disorder that leads to rapidly progressive paralysis and respiratory failure. Frontotemporal dementia (FTD) is the most common form of dementia in the population under the age of 65.<br /><br />This landmark discovery has impacted how these neurological disorders are diagnosed, investigated and perceived. It also provides a distinct therapeutic target for gene therapy efforts aimed at ameliorating these diseases.

Human Genetics & Genetic Disease
JUL 2013 17
Real Time PCR Experimental Design and Analysis Amplified with NuPCR Reagents
More Info +

Quantitative Real-Time PCR (qPCR) has been the technique of choice for gene expression analysis studies for decades. Although effective, current probe-based assays can exhibit cross-reactivity issues, require tedious design procedures, and involve expensive reagents. NuPCR reagents constitute a novel approach that uses a unique NuZyme™ complex for cost-effective, sensitive, and specific qPCR on any Real-Time PCR instrument. In addition, web-based DesignStudio™ software is available to simplify assay design and ordering. 

In this webinar, Gothami Padmabandu will discuss NuPCR chemistry and the ease of designing duplexed assays. In addition, experimental design and data analysis using NuPCR reagents in a number of different qPCR applications will be presented.

None
JUN 2013 19
Identification of rare disease-causing variants using next-generation sequencing
More Info +

Activating mutations in the GNAQ gene can lead to Sturge-Weber Syndrome, a rare disease affecting 1 in 20,000 people. Mutations in this same gene can also cause port-wine stain birthmarks affecting 1 in 333 individuals. In this presentation, Dr. Jonathan Pevsner of Kennedy Krieger Institute will describe his lab's research using whole-genome and targeted resequencing to identify causative variants of these somatic mosaic conditions. The presentation will also discuss the use of Illumina's TruSight Autism content set for the detection of variants associated with Autism Spectrum Disorder. 

Human Genetics & Genetic Disease
JUN 2013 13
Latest Developments in Molecular Pathology (MoPath) Rate Setting
More Info +

In May 2013, the Centers for Medicare and Medicaid Services (CMS) proposed new payment rates for the new MoPath codes. Many laboratories are concerned that these rates undervalue key test areas, including molecular cytogenomic, inherited disease, and cancer testing.
July 8 is the final deadline to respond to these rates and propose new values.

In this webinar, you will learn:

● About the latest developments in MoPath rate setting
● How to participate in the rate setting process to ensure appropriate reimbursement for future molecular diagnostic tests
● How and when to respond to the current rate proposal

Diagnostics
MAY 2013 30
Sequencing analysis of tissue samples: Fresh frozen vs. FFPE
More Info +

We'll discuss:

  • Analyzing small sample sizes of FFPE material
  • Obtaining FFPE results that are consistent with fresh-frozen results
  • Specially developed tools for comparing results
Cancer Genomics
MAY 2013 22
Assembling and Analyzing Illumina Data in DNASTAR Lasergene Software
More Info +

Join us to learn how to simplify your data analysis workflows for Illumina sequencing experiments. DNASTAR Lasergene software is a set of genomic assembly and analysis tools that provide a simple, yet highly flexible environment for RNA profiling, reference-guided and de novo sequence assembly, and many other workflows. During this presentation, Matthew Keyser of DNASTAR will demonstrate sequence assembly and analysis of Illumina data using Lasergene. The demonstration will include:

  • Multiple exome assembly and comparison
  • RNA-Seq alignment and analysis
  • Microbial genome assembly with gap closure
  • SeqMan NGen for de novo genome assembly on the Illumina BaseSpace® platform
Software
MAY 2013 02
Exploring the Home, Hospital, and Human Microbial Interactome – The H3MP Study
More Info +

Through next-generation sequencing, microbial genomic research is accelerating the pace of discovery–rapidly expanding our understanding of microbial function and interactions.

Metagenomic and microbiome studies provide researchers deep insight about the microbes that populate our surroundings, infrastructure, and built environments. In this webinar, Dr. Jack Gilbert will present initial findings from the Hospital Microbiome Project. The goal of this ongoing initiative is to characterize the taxonomic composition of surface, air, water and human-associated communities in a new hospital—starting from the introduction of patients to major surgical procedures. Please join us to see Dr. Gilbert present preliminary data and discuss what his team has discovered from this exciting endeavor.

Sequencing
APR 2013 17
Optimizing the Utility of Forensic Human Mitochondrial DNA Analysis
More Info +

Our laboratory has developed a protocol designed to generate whole mitochondrial genome (mt-genome) sequencing data from robust DNA samples, such as those obtained from buccal swabs and blood stains. This approach uses a long PCR amplification technique with two overlapping primer sets, covering the entire human mt-genome. Pooled amplicons are prepared with the Nextera XT™ DNA Sample Preparation Kit and rapidly sequenced on the MiSeq system, generating high-throughput sequencing data that can be quickly analyzed using the on-board software as well as third-party software tools. Data quality is sufficient to easily determine the presence of expected polymorphisms in the samples. In addition, the deep sequencing results on carefully prepared mixtures are able to detect the presence of minor variants at the expected positions, providing a heightened level of detection of minor sequence variants. Results from single source and mixed DNA samples underscore the value and sensitivity of Illumina sequencing data, relative to Sanger sequencing, in providing increased resolution of forensic mtDNA samples.

Forensic Genomics
MAR 2013 14
Genomic Sequencing in the Clinical Laboratory: Lessons Learned and Best Practices
More Info +

Genome sequencing for clinical use has the potential to reduce diagnostic odysseys, refine diagnostic evaluations, increase our understanding of prognoses, and improve patient care. In order to establish whole-genome sequencing as another tool at the physician's disposal, several components must be carefully developed and evaluated. Among these are physician and patient support, informed consent, secure data management, and, critically, the analytical quality of the data generated for clinical interpretation. As we move towards an era of genomic testing and increase our knowledge of the genome, analytical validity becomes increasingly important. In this webinar we discuss the lessons and best practices learned by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.

Sequencing:Services
DEC 2012 11
Learn How the Illumina Genome Network (IGN) Has Been Instrumental in Providing Fast, Reliable Whole Human Genome Sequencing Data
More Info +

Chris Mason describes how he used the Illumina Genome Network (IGN) for low input, whole-genome sequencing of rare clinical cases with extreme phenotypes from the NIH's Undiagnosed Disease Program (UDP) and a consanguineous family with neural-tube defects (NTDs). For all sequenced samples, the IGN data provided high coverage across the genome, including regulatory regions like promoters and enhancers, allowing the research team to pinpoint likely genes for the disease phenotypes. A comparison of output data from IGN software suite (CASAVA/GROUPER) to SAMtools/GATK revealed a high overlap of SNVs and indels between software platforms. The variants specific to each software suite showed higher Ti/Tv ratio. Overall, the results highlight the ease and speed of whole-genome sequencing services for identifying disease phenotypes. The genetic data can be combined with other biological modalities (transcriptional, epigenetic, proteomic) to function as a systems biology approach for personalized medicine.

Sequencing:Services
DEC 2012 05
Transcriptome analyses in individual cells using Smart-Seq
More Info +

Methods for global gene expression analysis in individual cells have important applications in biology and medicine. This webinar describes the Smart-Seq protocol for polyA+ RNA analysis, applicable at single-cell levels. Compared to existing methods, the Smart-Seq protocol has improved read coverage across transcripts, significantly enhancing analysis of alternative transcript isoforms and improving SNP identification. The sensitivity and quantitative accuracy of the Smart-Seq method for single-cell transcriptomics have been evaluated with total RNA dilution and spike-in RNAs. This method has been proven using cancer cell lines, circulating tumor cells from melanomas, and early embryonic cells. The Smart-Seq protocol provides a robust method for addressing fundamental biological questions that require transcriptome profiling in rare or single cells.

Sequencing
NOV 2012 28
Outbreak - The Sequel: Using Next-gen Sequencing to Unravel Outbreaks of Infectious Disease
More Info +

When an infectious disease outbreak occurs, public health officials attempt to identify where it started and how it spread so that they can initiate appropriate control and prevention strategies. Using a combination of field epidemiology (interviewing cases and controls) and molecular epidemiology (genotyping of bacterial or viral pathogens), they attempt to establish links between cases and develop a putative reconstruction of the outbreak. Unfortunately, the low resolution of molecular epidemiology techniques currently available to most reference microbiology laboratories cannot provide detailed information on the underlying transmission dynamics within an outbreak. However, next-generation sequencing offers exciting new possibilities for tracking disease outbreaks with high resolution. Over the course of an outbreak, a small amount of genetic variation accrues in a pathogen's genome as a result of mutations. By tracking the presence or absence of these mutations in all pathogen genomes from a given outbreak, it is possible to identify where particular variants arose and trace person-to-person transmission events. This webinar will provide an introduction to this emerging field of genomic epidemiology, highlighting the application of this approach to reconstruct outbreaks of tuberculosis in British Columbia, Canada.

Sequencing
OCT 2012 02
Evolving tools for understanding the functional genome: RNA-Seq and the ENCODE Project
More Info +

RNA-Seq is a powerful tool for studying various aspects of RNA biology, including expression levels, alternative splicing, RNA editing, and gene discovery. Though RNA-Seq has long been in use, robust and easy methods for generating strand-specific libraries and libraries from total RNA samples have not been commercially available. The new Illumina Tru-Seq Strand-specific Total RNA-Seq kits facilitate the generation of high quality libraries via a simple, rapid, and familiar workflow. I will present modENCODE data generated using these new kits and compare the results to those generated from libraries prepared using previous Illumina RNA-Seq kits and the same RNA samples. Specifically, I will discuss the degree of strandedness, evenness of coverage, and discovery of transcribed regions not identified using poly(A)-selected RNA-Seq libraries.

Sequencing
 

  • *
  • *
  • *
  • *
  • *

SUBMIT